deferasirox has been researched along with Thrombopenia in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Fu, R; Huang, L; Liu, C; Liu, Z; Tian, M | 1 |
Fujita, T; Haba, R; Nishiuchi, T; Ohnishi, H; Okutani, Y; Yoshida, K | 1 |
2 other study(ies) available for deferasirox and Thrombopenia
Article | Year |
---|---|
Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation-related apoptosis.
Topics: Apoptosis; Benzoates; Deferasirox; Humans; Hydrazines; Iron; Iron Chelating Agents; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia | 2022 |
Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome.
Topics: Aged; Anemia; Benzoates; Chronic Disease; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Radiography; Thrombocytopenia; Transfusion Reaction; Triazoles | 2010 |